Immunotherapy drug shows promise for rare, aggressive thyroid cancer
NCT ID NCT05119296
First seen Jan 08, 2026 · Last updated Apr 30, 2026 · Updated 27 times
Summary
This study tests whether the immunotherapy drug pembrolizumab (Keytruda) can shrink or control anaplastic thyroid cancer, a rare and aggressive type. The trial includes 12 adults whose cancer has spread or cannot be removed and who have no other treatment options. Participants receive pembrolizumab every 3 weeks, and the study measures how many patients see their tumors shrink or disappear.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Stanford University
Palo Alto, California, 94305, United States
Conditions
Explore the condition pages connected to this study.